• MDV3100 (Enzalutamide): Decoding AR-Driven Senescence in Pro

  2026-07-08

  Explore how MDV3100 (Enzalutamide) shapes prostate cancer research by modulating androgen receptor signaling and senescence phenotypes. This article delivers in-depth insights and practical guidance for advanced assay design, distinguishing itself through a focused analysis of context-dependent therapy-induced senescence.

• CPI-613: Experimental Workflows Transforming Tumor Cell Meta

  2026-07-08

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) enables targeted inhibition of mitochondrial metabolism, empowering researchers to dissect apoptosis mechanisms and chemoresistance in cancer. This article provides hands-on workflows, protocol tips, and troubleshooting strategies to maximize CPI-613’s impact in acute myeloid leukemia and non-small cell lung carcinoma models.

• Olsalazine Sodium: Protocols and Innovations for Cancer Rese

  2026-07-07

  Olsalazine Sodium, a validated mesalamine dimer, is transforming inflammation and colorectal cancer models through precisely quantifiable LTB4 chemotaxis inhibition and versatile anti-inflammatory action. This article breaks down advanced workflows, experimental enhancements, and troubleshooting strategies that unlock its full research value—bridging innovation from xenobiotic transport studies to tumor biology.

• Sumatriptan’s Anti-Inflammatory Role: Systematic Review Insi

  2026-07-07

  Ala et al. systematically reviewed evidence showing sumatriptan, beyond its established anti-migraine activity, exhibits significant anti-inflammatory effects via modulation of cytokines, nitric oxide signaling, and peptide release. These findings broaden the mechanistic understanding and potential applications of sumatriptan in inflammation-driven pathologies.

• Brefeldin A: Dissecting ER Stress and Endothelial Dynamics i

  2026-07-06

  Discover how Brefeldin A (BFA) enables advanced ER stress and apoptosis induction in cancer and endothelial biology. This in-depth review uncovers its unique mechanistic impact on vesicle transport and cytoskeletal remodeling, with translational insights for colorectal and breast cancer research.

• Berberrubine Chloride Regulates Urate Transport and JAK2/STA

  2026-07-06

  This study demonstrates that berberrubine, a key metabolite of berberine, robustly lowers serum uric acid and attenuates renal inflammation in mouse models of hyperuricemia. The work elucidates a dual mechanism involving modulation of urate transporters and suppression of the JAK2/STAT3 pathway, providing a mechanistic foundation for its application as an anti-hyperuricemia agent in preclinical research.

• Viral Control of RIPK3 Degradation Modulates Necroptosis and

  2026-07-05

  Liu et al. reveal a novel viral strategy in orthopoxviruses, where a class of viral proteins (vIRD) trigger the targeted degradation of RIPK3, thereby suppressing necroptosis and modulating virus-induced inflammation. These insights advance our understanding of host-pathogen interactions and offer new perspectives for studying ubiquitylation and immune regulation.

• 3-Aminobenzamide (PARP-IN-1): Applied Workflows and Innovati

  2026-07-04

  3-Aminobenzamide (PARP-IN-1) elevates experimental precision for researchers exploring poly (ADP-ribose) polymerase inhibition in oxidative stress, vascular, metabolic, and emerging antiviral models. Its highly selective inhibition, robust solubility, and proven cross-domain versatility empower reproducible results and deeper mechanistic insights.

• 25-Hydroxycholesterol Drives Immunosuppressive TAM Reprogram

  2026-07-03

  Xiao et al. (2024) elucidate how 25-hydroxycholesterol accumulation in tumor-associated macrophages (TAMs) modulates lysosomal AMPK activation and STAT6 phosphorylation, reinforcing immunosuppressive phenotypes. This immunometabolic pathway positions CH25H as a target to improve anti-tumor immunity and responses to checkpoint blockade.

• Annexin V-FITC/7-AAD Apoptosis Kit: Technical Application Gu

  2026-07-03

  The Annexin V-FITC/7-AAD Apoptosis Kit provides a rapid and reliable method for distinguishing apoptotic from necrotic cells in cultured samples, supporting rigorous cell death analysis in research settings. It is best suited for flow cytometry and fluorescence microscopy-based cell viability and cytotoxicity assays, but is not intended for mechanistic pathway elucidation or use with unconventional specimens. Proper handling and protocol adherence are essential for reproducible results.

• Decitabine Enhances Anti–PD-1 Efficacy via CD8+ T Cell Repro

  2026-07-02

  This study demonstrates that low-dose decitabine primes CD8+ progenitor exhausted T cells, amplifying their expansion and cytolytic function in combination with anti–PD-1 therapy. The findings highlight a mechanistic basis for improved immunotherapy responses in solid tumor models, with implications for optimizing epigenetic modulation strategies in cancer research.

• Caspase-3 Fluorometric Assay Kit: Precision Apoptosis Detect

  2026-07-02

  The Caspase-3 Fluorometric Assay Kit delivers quantitative, DEVD-dependent detection of caspase-3 activity, a cysteine-dependent aspartate-directed protease central to apoptosis. Its one-step protocol enables sensitive measurement in diverse biological contexts, supporting robust apoptosis assay workflows.

• Etoposide (VP-16): Advanced Applications in Senescence Resea

  2026-07-01

  Explore how Etoposide (VP-16) empowers next-generation cancer and aging research by enabling precise DNA damage assays and senescence modulation. This in-depth review unveils fresh applications, protocols, and mechanistic insights beyond standard oncology approaches.

• OTUD3 Stabilizes SLC7A11 to Drive Sunitinib Resistance in cc

  2026-07-01

  This article analyzes how OTUD3-mediated stabilization of SLC7A11 suppresses ferroptosis, promoting sunitinib resistance in clear cell renal cell carcinoma (ccRCC). The study employs biochemical and cell-based assays to elucidate the mechanism, offering insight into potential strategies for overcoming drug resistance via ferroptosis modulation.

• VE-822 ATR Inhibitor: Advanced Radiosensitization in Tumor M

  2026-06-30

  Explore the role of VE-822 as a potent ATR inhibitor in enhancing tumor radiosensitivity, focusing on experimental strategies in physiologically relevant 3D models. This article delivers unique insights for DNA damage response inhibition and cancer chemoradiotherapy research.

13863 records 1/925 page Next 12345 下5页 Last page